Abstract 1156P
Background
The introduction of immune checkpoint inhibitors (ICIs) has transformed the treatment of advanced melanoma. However, treatment comes with the risk of immune-related adverse events (irAEs). Especially now that immunotherapy has moved to the adjuvant setting, doctors and patients must weigh potential benefits versus risks based on as much available information as possible. Real-world data are essential for decision-making.
Methods
A nationwide study on irAEs in Danish real-world patients treated with adjuvant anti-PD1 therapy for resected stage III-IV melanoma from 2018-2022. Data were retrieved from two national databases, the IMMUNOTOX database and the Danish Metastatic Melanoma Database (DAMMED).
Results
Data from 792 patients were included. The majority of patients were male (55%) with a median age of 62 (range 16-88) at time of first treatment. In total, 697 patients (88%) experienced an irAE, the most common being fatigue (44%). Low-grade irAEs (grades 1-2) were very common, whereas different subtypes of severe irAEs (grades 3-5) were observed in 0.3-4%. In total, 121 patients (15.3%) experienced severe irAEs out of which five patients (0.6%) died due to irAE. Having at least one irAE was associated with a lower risk of melanoma relapse. Seasonal variation was observed with more frequent debut of organ-specific (gastrointestinal, ocular, musculoskeletal, and thyroid) irAEs during summer, while mild skin toxicities were more frequent in the winter period.
Conclusions
In this nationwide cohort of real-world adjuvant melanoma patients, we observe that having any grade of irAEs, as well as a severe irAE, is slightly more frequent compared to clinical phase III trials and comparable to previously published real-world studies. Further, the risk of relapse from melanoma is lower among patients experiencing an irAE. Finally, significant seasonal variation in irAE incidence was observed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
E. Ellebæk: Financial Interests, Personal, Invited Speaker: Pierre Fabre, BMS, Novartis, MSD, Pfizer; Other, Travel and conference expenses: MSD, Pierre Fabre. R.B. Holmstroem: Non-Financial Interests, Personal, Invited Speaker, Talk on Immune-related adverse events: Best Practice Nordic. M. Donia: Financial Interests, Personal, Invited Speaker, Teaching: Novartis, Roche; Financial Interests, Personal, Other, Advisor: Achilles Therapeutics; Non-Financial Interests, Other, Sub-investigator of clinical trial with connected translational research: Bristol Myers Squibb; Non-Financial Interests, Personal, Proprietary Information, Proprietary data access: Bristol Myers Squibb; Non-Financial Interests, Personal, Proprietary Information, Proprietary Data Access: Genentech; Other, Chairman of the Melanoma and Non-melanoma Skin Cancer Scientific Committee: Danish Medicines Council (Medicinrådet). C.A. Haslund: Financial Interests, Personal, Invited Speaker: MSD, GSK, BMS; Financial Interests, Institutional, Local PI: BMS, Tesaro, MSD, IO Biotech, Chimerix, Incyte; Financial Interests, Institutional, Coordinating PI: GSK, Celgene Aps. L. Bastholt: Non-Financial Interests, Advisory Role, Scientific Committee under Danish Medicines Agency regarding new Treatments of Melanoma, Skin Cancer and Thyroid Cancer: Danish Medicines Agency. I. Svane: Financial Interests, Personal, Advisory Board: BMS, Pierre Fabre, Novartis; Financial Interests, Personal, Invited Speaker: MSD, Pierre Fabre, Novartis, Roche, BMS; Financial Interests, Personal, Writing Engagement: MSD; Financial Interests, Personal, Stocks/Shares, Cofounder and Founder warrants: IO Biotech; Financial Interests, Institutional, Research Grant: Adaptimmune, Enara Bio, Lytix Biopharma, TILT Biotherapeutics; Financial Interests, Institutional, Funding: Evaxion; Non-Financial Interests, Principal Investigator: BMS, Novartis, Roche, TILT Biotherapeutics, Lytix Biopharma. All other authors have declared no conflicts of interest.
Resources from the same session
1129P - Effect of subsequent therapies including checkpoint inhibitors on overall survival in a phase III randomized trial of tebentafusp in first-line metastatic uveal melanoma: Long-term follow-up
Presenter: Marlana Orloff
Session: Poster session 13
1130P - Tebentafusp (tebe) in an ongoing cohort of 72 French patients (pts) with metastatic uveal melanoma (mUM)
Presenter: Leah Mailly-Giacchetti
Session: Poster session 13
1131P - Management of metastatic uveal melanoma (MUM) patients on tebentafusp in a real-world setting
Presenter: Mauricio Fernando Ribeiro
Session: Poster session 13
1132P - Chemokine expression in uveal melanoma and association with tumor genetics and response to immunotherapy
Presenter: Aparna Nallagangula
Session: Poster session 13
1133P - SF3B1 mutation predicts improved overall survival in metastatic uveal melanoma patients: Molecular and clinical correlates
Presenter: Luis del Carpio Huerta
Session: Poster session 13
1134P - Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)
Presenter: Isabella Glitza
Session: Poster session 13
1135P - Comparison of intracranial (IC) response assessment criteria in patients (pts) with melanoma brain metastases (MBM) treated with combination nivolumab (NIVO) plus ipilimumab (IPI) in CheckMate 204
Presenter: Raymond Huang
Session: Poster session 13
1136P - Regorafenib combined with BRAF-/MEK-inhibitors for the treatment of refractory melanoma brain metastases
Presenter: Iris Dirven
Session: Poster session 13
1138P - Intralesional administration of L19IL2/L19TNF in difficult-to-treat non-melanoma skin cancer shows a favorable safety profile and preliminary clinical activity
Presenter: Lukas Flatz
Session: Poster session 13